Adiso Therapeutics Unveils Promising Phase 1 Study Results for Neutrophil Modulator ADS051 in Gastroenterology Journal Adiso Therapeutics has revealed Phase 1 study results of ADS051, a groundbreaking neutrophil modulator, demonstrating safety and potential efficacy in treating ulcerative colitis, published in a prominent journal.

Adiso Therapeutics Unveils Promising Phase 1 Study Results for Neutrophil Modulator ADS051 in Gastroenterology Journal #United_States #Ulcerative_Colitis #Concord #Adiso_Therapeutics #ADS051